| Literature DB >> 8825693 |
Abstract
Ergotamine has been used for many years in the treatment of migraine, although there is little formal clinical evidence that it is significantly more efficacious than placebo. A number of side effects associated with ergotamine have been reported in the literature, including myocardial infarction, ischaemia of limb extremities, and fibrotic changes. Long-term use has led to reported cases of ergotamine-induced headache, vascular reactivity, and subclinical ergotism. When the safety profile of this drug is considered, coupled with its debatable efficacy from a clinical review previously published, the resulting poor risk:benefit ratio brings into question the continued use of ergotamine as a migraine treatment and calls for better controlled trials of its efficacy, or lack of, in the acute treatment of migraine.Entities:
Mesh:
Substances:
Year: 1996 PMID: 8825693 DOI: 10.1046/j.1468-2982.1996.1601005.x
Source DB: PubMed Journal: Cephalalgia ISSN: 0333-1024 Impact factor: 6.292